The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease
dc.contributor.author | Liu, Yu | |
dc.contributor.author | Jin, Xi | |
dc.contributor.author | Hong, Hyokyoung G. | |
dc.contributor.author | Xiang, Liyuan | |
dc.contributor.author | Jiang, Qingyao | |
dc.contributor.author | Ma, Yucheng | |
dc.contributor.author | Chen, Zude | |
dc.contributor.author | Cheng, Liang | |
dc.contributor.author | Jian, Zhongyu | |
dc.contributor.author | Wei, Zhitao | |
dc.contributor.author | Ai, Jianzhong | |
dc.contributor.author | Qi, Shiqian | |
dc.contributor.author | Sun, Qun | |
dc.contributor.author | Li, Hong | |
dc.contributor.author | Li, Yi | |
dc.contributor.author | Wang, Kunjie | |
dc.date.accessioned | 2020-09-02T14:58:28Z | |
dc.date.available | WITHHELD_12_MONTHS | |
dc.date.available | 2020-09-02T14:58:28Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Liu, Yu; Jin, Xi; Hong, Hyokyoung G.; Xiang, Liyuan; Jiang, Qingyao; Ma, Yucheng; Chen, Zude; Cheng, Liang; Jian, Zhongyu; Wei, Zhitao; Ai, Jianzhong; Qi, Shiqian; Sun, Qun; Li, Hong; Li, Yi; Wang, Kunjie (2020). "The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease." The FASEB Journal (8): 11200-11214. | |
dc.identifier.issn | 0892-6638 | |
dc.identifier.issn | 1530-6860 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/156429 | |
dc.description.abstract | The relationship of gut microbiota and calcium oxalate stone has been limited investigated, especially with no study of gut microbiota and short chain fatty acids (SCFAs) in nephrolithiasis. We provided Sprague Dawley rats of renal calcium oxalate stones with antibiotics and examined the renal crystals deposition. We also performed a case‐control study by analyzing 16S rRNA microbial profiling, shotgun metagenomics and SCFAs in 153 fecal samples from non‐kidney stone (NS) controls, patients with occasional renal calcium oxalate stones (OS) and patients with recurrent stones (RS). Antibiotics reduced bacterial load in feces and could promote the formation of renal calcium crystals in model rats. In addition, both OS and RS patients exhibited higher fecal microbial diversity than NS controls. Several SCFAs‐producing gut bacteria, as well as metabolic pathways associated with SCFAs production, were considerably lower in the gut microbiota among the kidney stone patients compared with the NS controls. Representation of genes involved in oxalate degradation showed no significance difference among groups. However, fecal acetic acid concentration was the highest in RS patients with high level of urinary oxalate, which was positively correlated with genes involvement in oxalate synthesis. Administration of SCFAs reduced renal crystals. These results shed new light on bacteria and SCFAs, which may promote the development of treatment strategy in nephrolithiasis. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | renal calcium oxalate stones | |
dc.subject.other | shotgun metagenomics | |
dc.subject.other | sgut microbiota | |
dc.subject.other | 16s Rrna | |
dc.subject.other | short chain fatty acids | |
dc.title | The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Biology | |
dc.subject.hlbtoplevel | Science | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156429/3/fsb220780.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156429/2/fsb220780-sup-0002-TableS1-S6.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156429/1/fsb220780_am.pdf | en_US |
dc.identifier.doi | 10.1096/fj.202000786R | |
dc.identifier.source | The FASEB Journal | |
dc.identifier.citedreference | Scheiman J, Luber JM, Chavkin TA, et al. Meta‐omics analysis of elite athletes identifies a performance‐enhancing microbe that functions via lactate metabolism. Nat Med. 2019; 25: 1104 ‐ 1109. | |
dc.identifier.citedreference | Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int. 2004; 72 ( Suppl 1 ): 1 ‐ 5. | |
dc.identifier.citedreference | Liu Y, Chen Y, Liao B, et al. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018; 5: 205 ‐ 214. | |
dc.identifier.citedreference | Sadaf H, Raza SI, Hassan SW. Role of gut microbiota against calcium oxalate. Microb Pathog. 2017; 109: 287 ‐ 291. | |
dc.identifier.citedreference | Tasian GE, Jemielita T, Goldfarb DS, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018; 29: 1731 ‐ 1740. | |
dc.identifier.citedreference | Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate‐degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985; 141: 1 ‐ 7. | |
dc.identifier.citedreference | Tavasoli S, Alebouyeh M, Naji M, et al. Association of intestinal oxalate‐degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case‐control study. BJU Int. 2020; 125: 133 ‐ 143. | |
dc.identifier.citedreference | Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2018; 46: 313 ‐ 323. | |
dc.identifier.citedreference | Koh A, De Vadder F, Kovatcheva‐Datchary P, Backhed F. From dietary fiber to host physiology: short‐chain fatty acids as key bacterial metabolites. Cell. 2016; 165: 1332 ‐ 1345. | |
dc.identifier.citedreference | Li L, Ma L, Fu P. Gut microbiota‐derived short‐chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017; 11: 3531 ‐ 3542. | |
dc.identifier.citedreference | Vaziri ND, Liu S‐M, Lau WL, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One. 2014; 9: e114881. | |
dc.identifier.citedreference | Khan S, Jena G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF‐β1‐induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem Toxicol. 2014; 73: 127 ‐ 139. | |
dc.identifier.citedreference | Xiang S, Zhou J, Li J, et al. Antilithic effects of extracts from different polarity fractions of Desmodium styracifolium on experimentally induced urolithiasis in rats. Urolithiasis. 2015; 43: 433 ‐ 439. | |
dc.identifier.citedreference | Yamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hep Intl. 2019; 13: 234 ‐ 244. | |
dc.identifier.citedreference | Oliphant K, Allen‐Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by‐products and their impact on host health. Microbiome. 2019; 7: 91. | |
dc.identifier.citedreference | Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019; 15 ( 5 ): 261 ‐ 273. https://doi.org/10.1038/s41574‐019‐0156‐z | |
dc.identifier.citedreference | Spiljar M, Merkler D, Trajkovski M. The immune system bridges the gut microbiota with systemic energy homeostasis: focus on TLRs, mucosal barrier, and SCFAs. Front Immunol. 2017; 8: 1353. | |
dc.identifier.citedreference | Juanola O, Ferrusquía‐Acosta J, García‐Villalba R, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J. 2019; 33: 11595 ‐ 11605. | |
dc.identifier.citedreference | Bultman SJ. Bacterial butyrate prevents atherosclerosis. Nat Microbiol. 2018; 3 ( 12 ): 1332 ‐ 1333. https://doi.org/10.1038/s41564‐018‐0299‐z | |
dc.identifier.citedreference | Heaney LM, Davies OG, Selby NM. Gut microbial metabolites as mediators of renal disease: do short‐chain fatty acids offer some hope? Future Sci OA. 2019; 5: Fso384. | |
dc.identifier.citedreference | Lee PC, Lee SY, Chang HN. Succinic acid production by Anaerobiospirillum succiniciproducens ATCC 29305 growing on galactose, galactose/glucose, and galactose/lactose. J Microbiol Biotechnol. 2008; 18: 1792 ‐ 1796. | |
dc.identifier.citedreference | Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12: 661 ‐ 672. | |
dc.identifier.citedreference | Pukall R, Lapidus A, Glavina Del Rio T, et al. Complete genome sequence of Conexibacter woesei type strain (ID131577). Stand Genomic Sci. 2010; 2: 212 ‐ 219. | |
dc.identifier.citedreference | Nishino K, Nishida A, Inoue R, et al. Analysis of endoscopic brush samples identified mucosa‐associated dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018; 53: 95 ‐ 106. | |
dc.identifier.citedreference | Moludi J, Alizadeh M, Lotfi Yagin N, et al. New insights on atherosclerosis: a cross‐talk between endocannabinoid systems with gut microbiota. J Cardiovascular Thorac Res. 2018; 10: 129 ‐ 137. | |
dc.identifier.citedreference | Franco‐de‐Moraes AC, de Almeida‐Pititto B, da Rocha Fernandes G, Gomes EP, da Costa Pereira A, Ferreira SRG. Worse inflammatory profile in omnivores than in vegetarians associates with the gut microbiota composition. Diabetol Metab Syndr. 2017; 9: 62. | |
dc.identifier.citedreference | Acharya A, Chan Y, Kheur S, et al. Salivary microbiome of an urban Indian cohort and patterns linked to subclinical inflammation. Oral Dis. 2017; 23: 926 ‐ 940. | |
dc.identifier.citedreference | Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008; 19: 1197 ‐ 1203. | |
dc.identifier.citedreference | Miller AW, Choy D, Penniston KL, Lange D. Inhibition of urinary stone disease by a multi‐species bacterial network ensures healthy oxalate homeostasis. Kidney Int. 2019; 96: 180 ‐ 188. | |
dc.identifier.citedreference | Ticinesi A, Milani C, Guerra A, et al. Understanding the gut‐kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018; 67: 2097 ‐ 2106. | |
dc.identifier.citedreference | Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016; 6: 34712. | |
dc.identifier.citedreference | Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018; 46: 503 ‐ 514. | |
dc.identifier.citedreference | Suryavanshi MV, Bhute SS, Gune RP, Shouche YS. Functional eubacteria species along with trans‐domain gut inhabitants favour dysgenic diversity in oxalate stone disease. Sci Rep. 2018; 8: 16598. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.